| Authors: |
Kantrowitz JT; 1 Schizophrenia Research Center, Nathan Kline Institute, Orangeburg, NY, USA jkantrowitz@nki.rfmh.org.; 2 Division of Experimental Therapeutics, Departments of Psychiatry and Neuroscience, Columbia University, New York, NY, USA., Epstein ML; 1 Schizophrenia Research Center, Nathan Kline Institute, Orangeburg, NY, USA.; 3 Graduate Center, City University of New York, New York, NY, USA., Beggel O; 1 Schizophrenia Research Center, Nathan Kline Institute, Orangeburg, NY, USA., Rohrig S; 1 Schizophrenia Research Center, Nathan Kline Institute, Orangeburg, NY, USA., Lehrfeld JM; 1 Schizophrenia Research Center, Nathan Kline Institute, Orangeburg, NY, USA., Revheim N; 1 Schizophrenia Research Center, Nathan Kline Institute, Orangeburg, NY, USA., Lehrfeld NP; 1 Schizophrenia Research Center, Nathan Kline Institute, Orangeburg, NY, USA., Reep J; 1 Schizophrenia Research Center, Nathan Kline Institute, Orangeburg, NY, USA., Parker E; 1 Schizophrenia Research Center, Nathan Kline Institute, Orangeburg, NY, USA., Silipo G; 1 Schizophrenia Research Center, Nathan Kline Institute, Orangeburg, NY, USA., Ahissar M; 4 Edmond and Lily Safra Center for Brain Sciences, Hebrew University of Jerusalem, Jerusalem, Israel., Javitt DC; 1 Schizophrenia Research Center, Nathan Kline Institute, Orangeburg, NY, USA.; 2 Division of Experimental Therapeutics, Departments of Psychiatry and Neuroscience, Columbia University, New York, NY, USA. |
